Marijuana Abuse Clinical Trial
Official title:
Selegiline for Treatment of Cannabis Dependence
During the past 15 years, the demand for treatment for marijuana-related problems in the United States has increased nearly twofold. Selegiline is a medication currently used to treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may be useful in treating individuals with marijuana dependence.
Behavioral therapy paired with drug therapy might be a more effective treatment approach to
marijuana dependence than behavioral therapy alone. Selegiline is a monoamine oxidase-B
inhibitor. It increases dopamine activity in parts of the brain that are involved in
dependence on addictive drugs such as nicotine, cocaine, and marijuana. Selegiline has been
effective in treating nicotine dependence, but has not yet been studied in treating
marijuana dependent individuals. The purpose of this study is to evaluate the effectiveness
of selegiline in treating marijuana dependent individuals. Specifically, this study will
determine whether selegiline reduces marijuana craving and withdrawal symptoms, thus leading
to reduction or abstinence in marijuana use.
Participants in this 9-week, double-blind, placebo-controlled study will be randomly
assigned to receive either selegiline (10 mg/day in two 5 mg pills) or placebo. Study visits
will occur twice each week. At each study visit, participants will complete self-reports and
urine toxicology tests. Throughout the study, participants will receive weekly individual
counseling. The counseling sessions will last 15 minutes. Reduction in marijuana use as well
as the number of weeks of consecutive marijuana abstinence will be evaluated.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01539525 -
Screening to Augment Referral to Treatment- Project START
|
Phase 2 | |
| Completed |
NCT00158249 -
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
|
Phase 2 | |
| Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
| Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
| Completed |
NCT00227903 -
Therapeutic Substance Abuse Treatment in Pregnancy - 1
|
Phase 2 | |
| Completed |
NCT00218478 -
Evaluating Responses to Drug-Related Cues Versus Neutral Cues to Understand the Effects of Marijuana Craving - 1
|
Phase 1 | |
| Completed |
NCT00227864 -
A Brief Marijuana Intervention for Adolescent Women - 1
|
Phase 3 | |
| Completed |
NCT00249509 -
Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
|
Phase 2 | |
| Completed |
NCT03717272 -
Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects
|
Phase 2 | |
| Completed |
NCT00142961 -
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
|
Phase 2 | |
| Terminated |
NCT02102230 -
CBT-I for Cannabis Use
|
N/A | |
| Completed |
NCT00580671 -
Treatment for Adolescent Marijuana Abuse
|
N/A | |
| Completed |
NCT00360269 -
Atomoxetine Treatment for ADHD and Marijuana Dependence
|
Phase 2 | |
| Completed |
NCT00227916 -
Motivational Interviews for Incarcerated Teens - 1
|
N/A | |
| Completed |
NCT03154567 -
Effects of Stress and Drug-cue Exposure (SCM)
|
Phase 1 | |
| Active, not recruiting |
NCT05322941 -
Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)
|
Phase 2 | |
| Completed |
NCT02797990 -
Conflict Between Maternal Autonomy and Child Health in Substance-use
|
N/A | |
| Completed |
NCT01762696 -
A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth
|
N/A | |
| Completed |
NCT03154580 -
Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users
|
Phase 1 | |
| Completed |
NCT00217971 -
Dronabinol Treatment for Marijuana Addiction
|
Phase 2 |